The FDA extended its review of Travere Therapeutics’ supplemental NDA for sparsentan (FILSPARI) in focal segmental glomerulosclerosis (FSGS), setting a new PDUFA target action date in April 2026. The agency requested additional characterization of clinical benefit, prompting the company to submit follow‑up data. Travere said the extension follows responses to FDA questions about benefit characterization. The company provided a corporate update and reiterated financials while preparing for an April action date. The extension is a routine regulatory step but delays potential label expansion that could broaden access and reimbursement. Drug developers and investors will watch the agency’s assessment of the additional data and any post‑approval commitments Travere may need to accept.